全文获取类型
收费全文 | 5931篇 |
免费 | 460篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 125篇 |
妇产科学 | 90篇 |
基础医学 | 1112篇 |
口腔科学 | 122篇 |
临床医学 | 509篇 |
内科学 | 1164篇 |
皮肤病学 | 178篇 |
神经病学 | 704篇 |
特种医学 | 234篇 |
外科学 | 494篇 |
综合类 | 13篇 |
一般理论 | 6篇 |
预防医学 | 585篇 |
眼科学 | 137篇 |
药学 | 347篇 |
中国医学 | 15篇 |
肿瘤学 | 538篇 |
出版年
2023年 | 58篇 |
2022年 | 92篇 |
2021年 | 186篇 |
2020年 | 123篇 |
2019年 | 164篇 |
2018年 | 159篇 |
2017年 | 182篇 |
2016年 | 192篇 |
2015年 | 233篇 |
2014年 | 257篇 |
2013年 | 335篇 |
2012年 | 505篇 |
2011年 | 512篇 |
2010年 | 291篇 |
2009年 | 273篇 |
2008年 | 393篇 |
2007年 | 424篇 |
2006年 | 372篇 |
2005年 | 360篇 |
2004年 | 299篇 |
2003年 | 290篇 |
2002年 | 234篇 |
2001年 | 39篇 |
2000年 | 31篇 |
1999年 | 37篇 |
1998年 | 37篇 |
1997年 | 39篇 |
1996年 | 18篇 |
1995年 | 21篇 |
1994年 | 24篇 |
1993年 | 15篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 12篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 12篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 7篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1971年 | 12篇 |
1969年 | 4篇 |
1928年 | 6篇 |
1923年 | 4篇 |
1921年 | 4篇 |
排序方式: 共有6407条查询结果,搜索用时 187 毫秒
61.
62.
63.
64.
Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. 总被引:7,自引:0,他引:7
Freddie Bray Anja H Loos Peter McCarron Elizabete Weiderpass Mark Arbyn Henrik M?ller Matti Hakama D Max Parkin 《Cancer epidemiology, biomarkers & prevention》2005,14(3):677-686
Despite there being sufficient evidence for the effectiveness of screening by cytology in preventing cancer of the cervix uteri, screening policies vary widely among European countries, and incidence is increasing in younger women. This study analyzes trends in squamous cell carcinoma (SCC) of the cervix uteri in 13 European countries to evaluate effectiveness of screening against a background of changing risk. Age-period-cohort models were fitted and period and cohort effects were estimated; these were considered as primarily indicative of screening interventions and changing etiology, respectively. A unique set of estimates was derived by fixing age slopes to one of several plausible age curves under the assumption that the relation between age and cervical cancer incidence is biologically determined. There were period-specific declines in cervical SCC in several countries, with the largest decreases seen in northern Europe. A pattern emerged across Europe of escalating risk in successive generations born after 1930. In the western European countries, a decrease followed by a stabilization of risk by cohort was accompanied by period-specific declines. In southern Europe, stable period, but increasing cohort trends, were observed. Substantial changes have occurred in cervical SCC incidence in Europe and well-organized screening programs have been highly effective in reducing the incidence of cervical SCC. Screening and changing sexual mores largely explain the changing period- and cohort-specific patterns, respectively. The increasing risk in recent cohorts is of obvious concern particularly in countries where no screening programs are in place. Further investigation of the effectiveness of opportunistic screening is warranted as is the observation of differing risk patterns in young cohorts in countries with relatively similar societal structures. 相似文献
65.
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. 总被引:4,自引:0,他引:4
Anja Henningsson Sharon Marsh Walter J Loos Mats O Karlsson Adam Garsa Klaus Mross Stephan Mielke Lucia Viganò Alberta Locatelli Jaap Verweij Alex Sparreboom Howard L McLeod 《Clinical cancer research》2005,11(22):8097-8104
PURPOSE: To retrospectively evaluate the effects of six known allelic variants in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes on the pharmacokinetics of the anticancer agent paclitaxel (Taxol). EXPERIMENTAL DESIGN: A cohort of 97 Caucasian patients with cancer (median age, 57 years) received paclitaxel as an i.v. infusion (dose range, 80-225 mg/m(2)). Genomic DNA was analyzed using PCR RFLP or using Pyrosequencing. Pharmacokinetic variables for unbound paclitaxel were estimated using nonlinear mixed effect modeling. The effects of genotypes on typical value of clearance were evaluated with the likelihood ratio test within NONMEM. In addition, relations between genotype and individual pharmacokinetic variable estimates were evaluated with one-way ANOVA. RESULTS: The allele frequencies for the CYP2C8*2, CYP2C8*3, CYP2C8*4, CYP3A4*3, CYP3A5*3C, and ABCB1 3435C>T variants were 0.7%, 9.2%, 2.1%, 0.5%, 93.2%, and 47.1%, respectively, and all were in Hardy-Weinberg equilibrium. The population typical value of clearance of unbound paclitaxel was 301 L/h (individual clearance range, 83.7-1055 L/h). The CYP2C8 or CYP3A4/5 genotypes were not statistically significantly associated with unbound clearance of paclitaxel. Likewise, no statistically significant association was observed between the ABCB1 3435C>T variant and any of the studied pharmacokinetic variables. CONCLUSIONS: This study indicates that the presently evaluated variant alleles in the CYP2C8, CYP3A4, CYP3A5, and ABCB1 genes do not explain the substantial interindividual variability in paclitaxel pharmacokinetics. 相似文献
66.
67.
68.
69.
70.
Predictors for successful PBSC collection on the fourth day of G‐CSF‐induced mobilization in allogeneic stem cell donors 下载免费PDF全文
Anja van Oostrum Jaap Jan Zwaginga Sandra Croockewit Jacqueline Overdevest Mirjam Fechter Bart Ruiterkamp Anneke Brand Tanja Netelenbos 《Journal of clinical apheresis》2017,32(6):397-404
Peripheral blood stem cells (PBSCs) used for allogeneic transplantation are collected by apheresis after pre‐treatment of donors with G‐CSF. Using modern apheresis devices stem cells can be collected more efficiently. It was studied whether collection on the 4th instead of the 5th day after initiation of G‐CSF treatment might be feasible. Stem cell yields that could have been collected on day 4 were calculated in two cohorts treated with 10 µg/kg G‐CSF once daily (n = 106, cohort I) or 5 µg/kg twice daily schedule (n = 85, cohort II). Harvests were predicted using the median collection efficiency (CE) of the apheresis machine and regarded successful when > 5.0 x106 CD34+/kg recipient body weight. Successful harvests at day 4 could have been obtained in only 22.6% and 41.2% of donors in cohort I and II respectively, while the expected successful collections on day 5 were 55.7% and 76.5%. Individual donor factors that correlated with a successful harvest on day 4 were weight, BMI, age, ratio donor/recipient weight and total G‐CSF dose in cohort I, whereas ratio donor/recipient weight was the only significant predictor in cohort II. Donor weight, BMI and total G‐CSF dose correlated positively with CD34+ values in the blood on day 4 in all donors. However, donor characteristics were not able to be used as strong predictors in daily practice. In conclusion, PBSC collection on day 4 will not result in a successful harvest in most stem cell donors, however using a twice daily G‐CSF scheme increases the yield. 相似文献